Categories: aggregated

Patient Zero for Untreatable Depression Begins Groundbreaking Psychedelics Therapy – Ending Depression Through Psilocybin?

In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.

Jason

Share
Published by
Jason

Recent Posts

The Latest in DEA Shenanigans? The Federal Agency Punts Marijuana Hearings into 2025

In this article, we're going to dive deep into why the DEA is dragging its…

1 day ago

The Red Wall Blocking Marijuana Legalization in America, Real or Imagined?

As the movement for marijuana legalization gains momentum across the United States, a significant barrier…

3 days ago

Autoimmune Conditions Are Rising Fast in American Medicine, Can Cannabis Help?

Conventional treatments prescribed to treat autoimmune conditions are focused on taming inflammation; these usually include…

3 days ago

Ohio Non-Medical Cannabis is available at Verilife

Verilife Non-Medical Cannabis is now available in Ohio. Open to customers 21+ with a valid…

4 days ago

Find Verilife in New York

At Verilife, there's always a stocked selection of top products & new favorites. Find the…

4 days ago